Bilirubin
Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations
Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback
Actionable Insights Powered by AI
Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback